drugset / Trial / NCT05549778
Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC
Phase 1/2
Completed
12 enrolled
Jiangnan University
Affiliated Hospital of Jiangnan University · collab
Non-randomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate clinical safety and efficacy of a gastric ulcer drug, polaprezinc (POL), with the AR-inhibitor abiraterone in Chinese patients with castration-resistant prostate cancer (CRPC).
Timeline
- Start
- 2021-01-06
- Primary completion
- 2023-01-20
- Completion
- 2023-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Polaprezinc | Unknown | 75 mg | — |
| Background | Abiraterone acetate | Small molecule | — | — |